transplant

Green traffic light

Pharma

FDA signs off on Omeros' stem cell transplant drug Yartemlea

The FDA has approved Omeros' Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Kevin Dunleavy Dec 26, 2025 12:46pm

Doctor holding diagram of kidneys

Hansa eyes FDA filing after ph. 3 win for kidney transplant med

Sep 25, 2025 12:37pm

AZ touts Ultomiris results in post-transplant complication trial

Jun 16, 2025 10:32am

Bristol Myers Squibb new sign outside

BMS's Orencia wins FDA nod for prevention of GVHD

Dec 15, 2021 3:25pm

Bristol Myers Squibb

BMS' Orencia snagged priority review in transplant rejection

Aug 23, 2021 11:02am

Alan and Aisha

DaVita and Kidney Foundation spur living donors—and patient asks

Jun 23, 2021 8:25am